February 9, 2024Open Access

Risk-based approach of bioanalytical methods for clinical immunogenicity assessment of multidomain biotherapeutics

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Tweetable abstract Risk-based bioanalytical method development for clinical antidrug antibody detection and characterization of multidomain biotherapeutics.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Mao et al. (Fri,) studied this question.

synapsesocial.com/papers/68e7a429b6db64358770c67d https://doi.org/https://doi.org/10.4155/bio-2023-0250

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Bispecific antibodies2021 · 142 citations
2Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk2019 · 30 citations
3Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics2019 · 23 citations
4The Center for Biologics Evaluation and Research2008 · 104 citations
5Immunogenicity Risk Assessment for Multi-specific Therapeutics2021 · 29 citations

Me gusta

Guardar

Ver artículo completo